Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of
patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective …

Emerging evidence on the role of the antitumor activity of the immune system has generated
great interest in immunotherapy even for tumors that were historically considered as …

Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has become a “game
changer” in the treatment of advanced non-small cell lung cancer (NSCLC). Its most …

Abstract Immune-checkpoint inhibitors (ICI), particularly inhibitors of the PD-1 axis, have
altered the management of non–small cell lung cancer (NSCLC) over the last 10 years. First …

Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

Lung cancer is one of the most common cancers and the leading cause of cancer-related
deaths worldwide. Most of these patients with non-small cell lung cancer (NSCLC) present …

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell
lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy …

Over the past decade, lung cancer treatment has undergone a major paradigm shift. A
greater understanding of lung cancer biology has led to the development of many effective …

Background Lung cancer is the leading cause of cancer‐related deaths worldwide and the
prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or …

Many decades in the making, immunotherapy has demonstrated its ability to produce
durable responses in several cancer types. In the last decade, immunotherapy has shown …